Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virol. May 25, 2021; 10(3): 97-110
Published online May 25, 2021. doi: 10.5501/wjv.v10.i3.97
Published online May 25, 2021. doi: 10.5501/wjv.v10.i3.97
Impact of COVID-19 in patients with lymphoid malignancies
John Charles Riches, Centre for Haemato-Oncology, Barts Cancer Institute - a Cancer Research UK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, United Kingdom
Author contributions: Riches JC performed the literature review, designed the paper, wrote the paper and prepared the figure.
Conflict-of-interest statement: The author has no conflicts of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: John Charles Riches, BM BCh, MA, MRCP, FRCPath, PhD, Clinical Senior Lecturer and Honorary Consultant Haemato-oncologist, Centre for Haemato-Oncology, Barts Cancer Institute - a Cancer Research UK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, 3rd Floor John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, United Kingdom. j.riches@qmul.ac.uk
Received: March 9, 2021
Peer-review started: March 9, 2021
First decision: April 6, 2021
Revised: April 8, 2021
Accepted: April 26, 2021
Article in press: April 26, 2021
Published online: May 25, 2021
Peer-review started: March 9, 2021
First decision: April 6, 2021
Revised: April 8, 2021
Accepted: April 26, 2021
Article in press: April 26, 2021
Published online: May 25, 2021
Core Tip
Core Tip: Patients with lymphoid malignancies who have coronavirus disease 2019 (COVID-19) severely enough to require hospital assessment have an approximately one-third chance of dying from the infection, representing a slightly greater than 2-fold increased risk compared to the general population. Despite initial concerns, treatment for lymphoma is not associated with increased risk for poor outcome. Current evidence for the efficacy of COVID-19 vaccines in patients with lymphoid malignancies is extremely limited, so it will be crucial to conduct studies to address this issue over the coming months.